<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450267</url>
  </required_header>
  <id_info>
    <org_study_id>FARM7K7XZB</org_study_id>
    <nct_id>NCT01450267</nct_id>
  </id_info>
  <brief_title>Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis</brief_title>
  <official_title>Randomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serafino A. Marsico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) is the most common inherited disease among the Caucasian population with
      considerable morbidity and reduced life expectancy.

      Excessive oxidants released by activated inflammatory cells and persisting infections are
      considered the main mechanism of damage of respiratory epithelium in CF.Glutathione (GSH)
      represents the first-line defence of the lung against oxidative stress-induced cell injury;
      however, a depletion of its levels has been observed in the airways of patients affected by
      CF. In vitro studies have showed that CFTR protein plays a pivotal role in transmembrane
      glutathione transport. Therapeutic approaches with inhaled GSH could improve the reduced lung
      antioxidant capacity in order to counterbalance the oxidant stress linked to the chronic
      airway inflammation and bacterial infection.

      Primary objective of the study is to investigate whether a 12 months treatment with inhaled
      GSH can improve airway obstruction in CF patients. Secondary objectives include the effects
      of GSH therapy on exercise capacity, body mass index (BMI), respiratory symptoms, quality of
      life, frequency of pulmonary exacerbations, hospital admissions, and antibiotic
      administration. Moreover the study will evaluate the effect of GSH therapy on markers of
      oxidative stress in exhaled breath condensate (EBC) and in serum, and on inflammatory markers
      on brushed nasal epithelial cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 eligible patients will be enrolled on the basis of inclusion criteria. Patients will be
      divided in two groups: 1) Group 1 age between 6 and 18 years; 2) Group 2 older than 18 years.
      Patients will be randomly assigned to the treatment or placebo arm.Patients randomized in the
      GSH arm will receive a dosage of 10 mg/kg bid over a 12 months period.

      Clinical visits will take place at the beginning (visit 0, enrolment visit) and after one
      month (visit 1), three months (visit 2), six months (visit 3) nine months (visit 4), and
      twelve months (visit 5, end of treatments).

      Follow-up clinical visits will take place one month (visit 6), three months (visit 7), six
      months (visit 8) after the end of treatments.

      At visit 0, all eligible patients will inhale GSH (10 mg/Kg) and a dynamic spirometry will be
      performed before, 10 and 60 minutes after inhalation. Patients showing a decrease in FEV1
      greater than 15% after GSH inhalation will be excluded from the study.

      At visit 0 and at each following visits (visit 1, 2, 3, 4, 5, 6, 7 and 8) will be performed
      and evaluated:

        -  Physical examination, measurement of vital signs, body temperature,BMI,and Spirometry;

        -  6 minute walking test;

        -  MMRC dyspnoea scale;

        -  Chronic cough impact questionnaire;

        -  Cystic Fibrosis Quality of Life Questionnaire;

        -  Number of pulmonary exacerbations;

        -  Number and duration of hospital admissions for pulmonary exacerbations;

        -  Number, duration and route of administration of antibiotics;

        -  Blood sampling for haematological and biochemical analysis;

        -  Brushing of nasal epithelial cell, exhaled breath condensate with evaluation of markers
           of oxidative stress (H2O2), and blood sample for the measurement of markers of oxidative
           stress in serum will be performed in a subgroup of patients at visits 0, 3, and 5.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in one second (FEV1) percent</measure>
    <time_frame>12 months</time_frame>
    <description>Increase of at least 15% of the percent of forced expiratory volume in one second (FEV1) after GSH therapy compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Small airway function</measure>
    <time_frame>12 months</time_frame>
    <description>It will be assessed by the flow volume curve and it will bealso evaluated after 1,3,6,and 9 months from the beginning of the treatments and after 1, 3, and 6 months from the end of the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>12 months</time_frame>
    <description>It will be measured by the six minutes walking test and it will be also evaluated after 1,3,6, and 9 months from the beginning of the treatments and after 1, 3, and 6 months from the end of the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>12 months</time_frame>
    <description>It will be also evaluated after 1,3,6, and 9 months from the beginning of the treatments and after 1, 3, and 6 months from the end of the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea</measure>
    <time_frame>12 months</time_frame>
    <description>It will be assessed through the Modified Medical Research Council (MMRC) dyspnoea scale and it will be also evaluated after 1,3,6, and 9 months from the beginning of the treatments and after 1, 3, and 6 months from the end of the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough</measure>
    <time_frame>12 months</time_frame>
    <description>It will be assessed by the Chronic Cough Impact Questionnaire (CCIQ)and it will be also evaluated after 1,3,6, and 9 months from the beginning of the treatments and after 1, 3, and 6 months from the end of the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>It will be assessed according to Cystic Fibrosis Quality of Life Questionnaire (CFQoL) (not for children 6-13 years old)and it will be also evaluated after 1,3,6, and 9 months from the beginning of the treatments and after 1, 3, and 6 months from the end of the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>It will be assessed evaluating the hospital admissions and antibiotic administrations. It will be also evaluated after 1,3,6, and 9 months from the beginning of the treatments and after 1, 3, and 6 months from the end of the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of oxidative stress (H2O2)in serum and in exhaled breath condensate (EBC)</measure>
    <time_frame>12 months</time_frame>
    <description>It will be measured at baseline, in the middle and at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelial inflammatory markers on brushed nasal epithelial cells</measure>
    <time_frame>12 months</time_frame>
    <description>Epithelial tyrosine phosphorylation, p38-MAPK phosphorylation, TNF alfa release will be evaluated at baseline, in the middle and at the end of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Physiological solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced Inhaled Glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Reduced Glutathione</intervention_name>
    <description>10 mg/kg, twice daily, 12 months</description>
    <arm_group_label>Reduced Inhaled Glutathione</arm_group_label>
    <other_name>GSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological solution</intervention_name>
    <description>0,13 ml/kg body weight, twice daily, 12 months</description>
    <arm_group_label>Physiological solution</arm_group_label>
    <other_name>0,9% sodium chloride sterile solution,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a confirmed diagnosis of cystic fibrosis documented by sweat chloride test over 60
             mmol/L and/or genotype analysis;

          -  male and female aged older than 6 years;

          -  stable clinical condition;

          -  written informed consent.

        Exclusion Criteria:

          -  pregnancy and fertile women taking oral contraceptives;

          -  cigarette smoking;

          -  positive culture for Burkholderia Cepacia;

          -  history of haemoptysis or pneumothorax;

          -  FEV1&lt;= 40% of the predicted value;

          -  hyperresponsiveness to GSH inhalation test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serafino A Marsico, PROF</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CECILIA CALABRESE, DR</last_name>
    <phone>00390817062365</phone>
    <email>cecilia.calabrese@unina2.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LIVIA DE PIETRO, DR</last_name>
    <phone>00390817062542</phone>
    <email>depietro.livia@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Monaldi, Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Raia, Prof</last_name>
      <email>raia@unina.it</email>
    </contact>
    <contact_backup>
      <last_name>Vincenzo Carnovale, Dr</last_name>
      <email>carnovale@unina.it</email>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Calabrese, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, Ratjen F, MÃ¼llinger B, Huber RM, Maier K, Rietschel E, Scheuch G. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med. 2004 Apr 1;169(7):822-8. Epub 2004 Jan 15.</citation>
    <PMID>14726422</PMID>
  </reference>
  <reference>
    <citation>Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest. 2005 Jan;127(1):308-17.</citation>
    <PMID>15653998</PMID>
  </reference>
  <reference>
    <citation>Raia V, Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Auricchio S, Cimmino M, Cavaliere M, Nardone M, Cesaro A, Malcolm J, Quaratino S, Londei M. Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax. 2005 Sep;60(9):773-80. Epub 2005 Jun 30.</citation>
    <PMID>15994249</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Serafino A. Marsico</investigator_full_name>
    <investigator_title>Professor of Respiratory Diseases</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Glutathione</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 11, 2016</submitted>
    <returned>June 16, 2016</returned>
    <submitted>September 11, 2016</submitted>
    <returned>October 27, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

